Recruiting soon

JointMedica Polymotion Resurfacing Device Outcomes for Hip Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Healthy
+1

+ Real World Data
+ Safety and Effectiveness
Over 21 Years
+4 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: July 2025

See protocol details

Summary

Principal SponsorJointMedica Inc.
Study ContactSteve Meakins
Last updated: July 23, 2025
Sourced from a government-validated database.Claim as a partner
Study start date: July 25, 2025Actual date on which the first participant was enrolled.

This study aims to evaluate the performance and safety of a hip implant device known as the JointMedica Polymotion Hip Resurfacing (PHR) device. It focuses on individuals who have already received this implant in Canada, New Zealand, and Australia. Up to 70 patients will be involved in this research to understand how well the implant is functioning over time. The study is important because it helps determine the durability and effectiveness of the implant, ensuring that it meets the needs of patients who rely on it for improved mobility and reduced pain. Participants will be asked to attend a follow-up visit as part of their standard care routine. During these visits, doctors will collect clinical data by conducting an x-ray of the hip and asking patients to fill out two questionnaires about their hip function and overall outcomes. The information collected, including the x-ray images, will be analyzed to see how well the implant is holding up, particularly the acetabular cup, which is a part of the hip joint. Researchers will look for any issues that might require additional surgery and monitor for any serious side effects related to the implant. This helps ensure that the device continues to be a safe and effective treatment option for patients.

Official TitleClinical and Radiographic Outcomes of the JointMedica Polymotion Resurfacing (PHR) Device 
Principal SponsorJointMedica Inc.
Study ContactSteve Meakins
Last updated: July 23, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
105 patients to be enrolledTotal number of participants that the clinical trial aims to recruit.
Case-only
These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

How participants are selected
Participants are selected without using randomization. They may be chosen based on convenience, access, or willingness to participate. This approach is common when random selection isn’t practical.
Another way to select participants is through a probability sample, where participants are chosen randomly, so everyone has an equal chance to be included.

How information is collected
Some studies use alternative or combined approaches that don't fit strictly into prospective, retrospective, or cross-sectional models. These may include hybrid timelines, simulations, or adaptive observational methods.Other Ways to Collect Data
Prospective: These studies collect new data moving forward over time.
Retrospective: These studies use existing medical records or past data.
Cross-sectional: These studies collect data at one single point in time.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
Over 21 YearsRange of ages for which participants are eligible to join.
Healthy volunteers allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Healthy
Real World Data
Safety and Effectiveness
Patient Reported Outcome (PRO)
Criteria
3 inclusion criteria required to participate
Age 21 or above at the time of the surgery
Have had the Polymotion Hip Resurfacing (PHR) (implanted between September 2020 to January 2025
Written informed consent given by subject
1 exclusion criteria prevent from participating
There is no exclusion criteria for this study

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives
One single intervention group 

is designated in this study

This study does not include a placebo group 

Treatment Groups
Group I
The patient group is the entire group of patients who have been implanted with the Polymotion Hip Resurfacing (PHR) system. This is the only group in the study, all patients will be assessed under the same criteria.
Study Objectives
Primary Objectives

The number of acetabular cups which are functional and not requiring additional surgical intervention following the primary implantation

Quantitative motion assessment of the acetabular cup at implantation and follow-up visit

Occurrence and severity of adverse events including necessitation of secondary surgical intervention.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 3 locations
Suspended
Mark RickmanAdelaide, AustraliaSee the location
Suspended
Gateway Surgery CentreCalgary, Canada
Suspended
Orthopaedic Specialist CentreAuckland, New Zealand
Recruiting soon3 Study Centers